V-CHECK is dedicated to provide reliable and cost-effective in vitro diagnostic products for women’s diseases, particularly for those without sensitive biomarkers for early diagnosis.
SUPERA PARQUE
SUPERA Park is an innovative environment that promotes knowledge transfer in several types of activities. It is responsible for attracting and retaining technology-based companies, with noteworthy mention to the Health, Biotechnology, Information Technology and Bioenergy industries. SUPERA Park was built within the University of São Paulo (USP) – one of the best universities in Brazil, Fact that makes it easier to find qualified people and hard science knowledge. SUPERA Park has many activities to support startups to validate and build a solid business model. Based on this, we have one of the best business incubator in Brazil (top 20 world universities in the 2019 UBI benchmark), 9 different laboratories for technical tests and validation, an international department and 3 clusters (health, software and beer) supported by our team. We also represent a number of startups that are looking for new partnerships and customers for their solutions. | SUPERA is the technology park of Ribeirão Preto, one of the most important scientific centers in the country. Our main programs are the Business Incubator, Open Innovation Program and Softlanding Program for international companies wishing to settle in Brazil. | SUPERA Innovation and Technology Park is a dynamic innovation ecosystem located in Ribeirão Preto, São Paulo, Brazil, and is linked to the University of São Paulo (USP) – Ribeirão Preto campus. SUPERA Park is a reference center for science, technology, and innovation, fostering entrepreneurship, knowledge-based businesses, and technological development. Core Mission: SUPERA Park supports the development and growth of startups, scale-ups, and innovative companies, particularly in the fields of biotechnology, life sciences, health, information technology, and advanced manufacturing. It provides infrastructure, business development support, and access to networks that drive innovation and competitiveness. Key Activities and Services: – Business Incubation and Acceleration: Programs for startups and scale-ups, offering mentoring, business modeling, market validation, and growth strategies. – Softlanding Programs: Support for international companies entering the Brazilian market and Brazilian companies aiming to internationalize. – Collaborative R&D Support: Facilitation of partnerships between companies, universities, and research centers for research, development, and innovation (R&D&I) projects. – Innovation Programs: Open innovation initiatives connecting corporations with startups and researchers to solve business challenges. – Infrastructure: High-standard office spaces, laboratories, coworking areas, and access to specialized facilities in biotechnology, pharmaceuticals, agritech, healthtech, and ICT. – Matchmaking and Networking: Connection to investors, corporate partners, academic experts, and government agencies to foster business and technology development. – International Cooperation: Support for international collaborative projects, technology transfer, and partnerships with global innovation ecosystems. Key Sectors of Focus: – Biotechnology – Pharmaceuticals and HealthTech – Medical Devices – Agritech and Bioinputs – Digital Health and ICT – Clean Technologies
Linearis
Linearis is transforming healthcare by merging artificial intelligence and biomarker analysis to enhance patient care with more precise, accessible prevention, detection, treatment of metabolic diseases including cancer, diabetes, and antimicrobial resistance. The team unites unparalleled, world-renowned experts in biomarker discovery, drug development, biopharma, and healthcare innovation. Alexandre Le Bouthillier, a serial AI entrepreneur and CEO, collaborates with Jacques Corbeil, holder of the Canada Research Chair in Medical Genomics and CSO, and Manon Boisclair, a global biopharma executive and COO/CCO. Together, they have discovered and internationally marketed medical diagnostics and treatments. Contributions from Yoshua Bengio, a co-father of modern AI and Turing Prize winner, David Wishart, curator of the Human Metabolome Database, bolster Linearis’ efforts in providing the first certified industrial laboratory that combines high-throughput metabolomic analysis and AI. | Linearis with its tandem Ventures Fund and Laboratory is pioneering and supporting discoveries to prevent, detect, and cure metabolomic diseases including cancer & diabetes through direct investments in innovative AI-powered life sciences companies. Linearis Ventures leverage its AI and multi-omics expertise to support life science companies’ growth, accelerating their trailblazing innovation and advancing biomarkers to provide critical insights into a broad spectrum of health conditions. Linearis Labs provide services to large biobanks, CROs and BioPharma companies across their life cycle management from drug discovery, patient screening, disease prevention as well as treatment monitoring.
Chitozan Health LLC
Chitozan Health is an antimicrobial company seeking to commercialize antimicrobial materials that minimize the tendency for resistance to develop in bacteria and fungal threats. We are currently focused on launch of an advanced burn and wound gel in collaboration with the Medical University of South Carolina and the Chief of Burn Surgery Dr. Steven Kahn. Other products in stages of development are an antimicrobial flame-resistant textile finish, an anti-fungal barrier packaging coating, topical skin disease treatments, and an inhaled therapeutic for treatment of chronic lung infections caused by pseudomonas aeruginosa and mycobacteria.
AlphaSense
AlphaSense is a market intelligence and search platform used by the world’s leading companies and financial institutions. Since 2011, our AI-based technology has helped professionals make smarter business decisions by delivering insights from an extensive universe of public and private content—including company filings, event transcripts, expert calls, news, trade journals, and equity research. Our platform is trusted by over 3,500 enterprise customers, including a majority of the S&P 500. Headquartered in New York City, AlphaSense employs over 1,000 people across offices in the U.S., U.K., Germany, Finland, and India. For more information, please visit www.alpha-sense.com. | The world’s most sophisticated companies rely on AlphaSense to remove uncertainty from decision-making. With market intelligence and search built on proven AI, AlphaSense delivers insights that matter from content you can trust. Our universe of public and private content includes equity research, company filings, event transcripts, expert calls, news, trade journals, and clients’ own research content. Founded in 2011, AlphaSense is headquartered in New York City with over 1,000 people across the globe and offices in the U.S., U.K., Finland, India, and Singapore. For more information, please visit www.alpha-sense.com. | AlphaSense is how the world’s most sophisticated companies remove uncertainty from their decision-making. With market intelligence and search built on proven AI, AlphaSense quickly delivers relevant insights from a trustworthy universe of public and private content—including equity research, company filings, event transcripts, expert calls, news, trade journals, and clients’ own research content. Headquartered in New York City, AlphaSense employs over 1,000 people across offices in the U.S., U.K., Finland, India, and Singapore. For more information, please visit www.alpha-sense.com. | AlphaSense is the AI platform redefining market intelligence and workflow orchestration, trusted by thousands of leading organizations to drive faster, more confident decisions in business and finance. The platform combines domain specific AI with a vast content universe of over 500 million premium business documents — including equity research, earnings calls, expert interviews, filings, news, and internal proprietary content. Purpose-built for speed, accuracy, and enterprise-grade security, AlphaSense helps teams extract critical insights, uncover market-moving trends, and automate complex workflows with high quality outputs. With AI solutions like Generative Search, Generative Grid, and Deep Research, AlphaSense delivers the clarity and depth professionals need to navigate complexity and obtain accurate, real-time information quickly. For more information, visit www.alpha-sense.com. | AlphaSense is the AI platform redefining market intelligence and workflow orchestration, trusted by thousands of leading organizations to drive faster, more confident decisions in business and finance. The platform combines domain specific AI with a vast content universe of over 500 million premium business documents. Purpose-built for speed, accuracy, and enterprise-grade security, AlphaSense helps teams extract critical insights, uncover market-moving trends, and automate complex workflows.
AGMI Group
AGMI Group is a global advisory and execution firm specializing in strategy and operations for life sciences and healthcare companies. With deep roots in biopharma, medtech, and diagnostics, we partner with industry leaders, venture-backed innovators, and private capital to drive value across R&D, commercialization, and investment cycles. Founded by a team of ex-McKinsey and industry executives, AGMI combines strategic rigor with hands-on execution, focusing on four core areas: 1. R&D Portfolio Strategy & IND Readiness (Preclinical to Translational) 2. Commercial and Go-to-Market Strategy 3. Private Capital – Due Diligence & Equity Story Development 4. Operational Excellence & PMO Execution AGMI Group operates globally with hubs in Boston, Silicon Valley, and Puerto Rico, supporting clients across the U.S., LATAM, Japan, and Southeast Asia. Our team includes MDs, PhDs, and operators who bridge science and strategy, execution and insight—driving results where it matters most.